Novel agents: Clinical trial design

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 148-153

  Tan, Antoinette R ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

105AD7; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; DECAY ACCELERATING FACTOR; IMATINIB; LONAFARNIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY APO2.7; UNCLASSIFIED DRUG;

CANCER RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DATA ANALYSIS; DIAGNOSTIC IMAGING; DISEASE MARKER; DRUG EFFICACY; DRUG RESEARCH; HUMAN; LEUKEMIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035173741     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28556     Document Type: Conference Paper

References (23)

1. Vaccine-induced apoptosis: A novel clinical trial end point?
2. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells
3. 6-benzylguanine for patients undergoing surgery for malignant glioma
4. 6-benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair
5. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
6. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition
7. Inhibition of phosphorylase kinase and tyrosine protein kinase activities by quercetin
8. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
9. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
10. Targeted therapy for chronic myelogenous leukemia with an Abl-specific tyrosine kinase inhibitor
11. Monitoring responses to antiangiogenic agents using noninvasive imaging tests
12. Optimal two-stage designs for phase II clinical trials
13. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint
14. There are no bad anticancer agents, only bad clinical trial designs-twenty- first Richard and Hinda Rosenthal Foundation Award Lecture
15. Designs for efficient clinical trials
16. Randomized phase II clinical trials
17. Phase II evaluation of thalidomide in patients with metastatic breast cancer
18. Investigating a sequence of randomized phase II trials to discover promising treatments
19. New methods for the design and analysis of clinical trials
20. Randomized discontinuation trials: Utility and efficiency
21. A clinical trial design avoiding undue placebo treatment